Statistical methods for building better biomarkers of chronic kidney disease

The last two decades have witnessed an explosion in research focused on the development and assessment of novel biomarkers for improved prognosis of diseases. As a result, best practice standards guiding biomarker research have undergone extensive development. Currently, there is great interest in the promise of biomarkers to enhance research efforts and clinical practice in the setting of chronic kidney disease, acute kidney injury, and glomerular disease. However, some have questioned whether biomarkers currently add value to the clinical practice of nephrology. The current state of the art pertaining to statistical analyses regarding the use of such measures is critical.

[1]  Lawrence Carin,et al.  Adversarial Time-to-Event Modeling , 2018, ICML.

[2]  O. Bruyère,et al.  A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density , 2016, Statistical methods in medical research.

[3]  Michael J Pencina,et al.  Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. , 2016, American heart journal.

[4]  Fei Wang,et al.  Merging multiple longitudinal studies with study‐specific missing covariates: A joint estimating function approach , 2015, Biometrics.

[5]  Michael J. Pencina,et al.  The Role of Physicians in the Era of Predictive Analytics. , 2015, JAMA.

[6]  M. Pencina,et al.  Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk. , 2015, Current opinion in lipidology.

[7]  Olga V. Demler,et al.  Tests of calibration and goodness‐of‐fit in the survival setting , 2015, Statistics in medicine.

[8]  B. Lo.  Sharing clinical trial data: maximizing benefits, minimizing risk. , 2015, JAMA.

[9]  Michael J. Pencina,et al.  Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease , 2015, Circulation.

[10]  B. van Calster,et al.  Calibration of Risk Prediction Models , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[12]  G. Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement , 2015, Annals of Internal Medicine.

[13]  I. White,et al.  Covariate-adjusted measures of discrimination for survival data , 2014, Biometrical journal. Biometrische Zeitschrift.

[14]  M. Pencina,et al.  Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives , 2014, Biometrical journal. Biometrische Zeitschrift.

[15]  J. Ioannidis,et al.  External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. , 2015, Journal of clinical epidemiology.

[16]  E. Steyerberg,et al.  The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. , 2014, European urology.

[17]  Ewout W. Steyerberg,et al.  F1000Prime recommendation of Calibration of risk prediction models: impact on decision-analytic performance. , 2014 .

[18]  Kathleen F. Kerr,et al.  Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[19]  C. Parikh,et al.  Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease. , 2014, Journal of the American Society of Nephrology : JASN.

[20]  Andrew J. Vickers,et al.  Does the Net Reclassification Improvement Help Us Evaluate Models and Markers? , 2014, Annals of Internal Medicine.

[21]  Olga V. Demler,et al.  Impact of correlation on predictive ability of biomarkers , 2013, Statistics in medicine.

[22]  M. Pencina,et al.  Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. , 2013, European urology.

[23]  A. Bansal,et al.  When does combining markers improve classification performance and what are implications for practice? , 2013, Statistics in medicine.

[24]  B L De Stavola,et al.  Methods for dealing with time‐dependent confounding , 2013, Statistics in medicine.

[25]  Kathleen F. Kerr,et al.  Testing for improvement in prediction model performance , 2013, Statistics in medicine.

[26]  Jialiang Li,et al.  Multicategory reclassification statistics for assessing improvements in diagnostic accuracy. , 2013, Biostatistics.

[27]  Arnovst Kom'arek,et al.  Clustering for multivariate continuous and discrete longitudinal data , 2013, 1304.4448.

[28]  M. Pencina,et al.  Evaluation of Markers and Risk Prediction Models , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  Kosuke Imai,et al.  Experimental designs for identifying causal mechanisms , 2013 .

[30]  B. Astor,et al.  Age and association of kidney measures with mortality and end-stage renal disease. , 2012, JAMA.

[31]  Sabine Van Huffel,et al.  Extending the c‐statistic to nominal polytomous outcomes: the Polytomous Discrimination Index , 2012, Statistics in medicine.

[32]  Ralph B D'Agostino,et al.  Misuse of DeLong test to compare AUCs for nested models , 2012, Statistics in medicine.

[33]  M. Pencina,et al.  Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.

[34]  Fei Wang,et al.  Quadratic inference function approach to merging longitudinal studies: validation and joint estimation , 2012 .

[35]  Margaret Sullivan Pepe,et al.  Biases introduced by choosing controls to match risk factors of cases in biomarker research. , 2012, Clinical chemistry.

[36]  Bradley P. Carlin,et al.  Clinically relevant graphical predictions from Bayesian joint longitudinal-survival models , 2012, Health Services and Outcomes Research Methodology.

[37]  Michael J. Pencina,et al.  Thoroughly Modern Risk Prediction? , 2012, Science Translational Medicine.

[38]  Hester F. Lingsma,et al.  Assessing the incremental value of diagnostic and prognostic markers: a review and illustration , 2012, European journal of clinical investigation.

[39]  B. Ledergerber,et al.  Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study , 2011, Statistics in medicine.

[40]  Harlan M Krumholz,et al.  A model for dissemination and independent analysis of industry data. , 2011, JAMA.

[41]  Thomas Lumley,et al.  American Journal of Epidemiology Practice of Epidemiology Evaluating the Incremental Value of New Biomarkers with Integrated Discrimination Improvement , 2022 .

[42]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[43]  Margaret S Pepe,et al.  Problems with risk reclassification methods for evaluating prediction models. , 2011, American journal of epidemiology.

[44]  Andrew J Vickers,et al.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. , 2011, Journal of the National Cancer Institute.

[45]  Yvonne Vergouwe,et al.  External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients. , 2010, American journal of epidemiology.

[46]  Dimitris Rizopoulos,et al.  JM: An R package for the joint modelling of longitudinal and time-to-event data , 2010 .

[47]  Joseph G Ibrahim,et al.  Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[49]  Tue Tjur,et al.  Coefficients of Determination in Logistic Regression Models—A New Proposal: The Coefficient of Discrimination , 2009 .

[50]  Nancy R Cook,et al.  Using relative utility curves to evaluate risk prediction , 2009, Journal of the Royal Statistical Society. Series A,.

[51]  David J. Hand,et al.  Measuring classifier performance: a coherent alternative to the area under the ROC curve , 2009, Machine Learning.

[52]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[53]  F. Harrell,et al.  Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.

[54]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[55]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[56]  M. Joffe,et al.  Hemoglobin variability and mortality in ESRD. , 2007, Journal of the American Society of Nephrology : JASN.

[57]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[58]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[59]  Guoqing Diao,et al.  Estimation of time‐dependent area under the ROC curve for long‐term risk prediction , 2006, Statistics in medicine.

[60]  J. Murabito,et al.  Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men , 2006, Annals of Internal Medicine.

[61]  Donald Hedeker,et al.  Longitudinal Data Analysis , 2006 .

[62]  Whole Grain Label Statements.  Guidance for Industry and FDA Staff , 2006 .

[63]  M. Pencina,et al.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.

[64]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[65]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[66]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[67]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[68]  J. Hilden.  The Area under the ROC Curve and Its Competitors , 1991, Medical decision making : an international journal of the Society for Medical Decision Making.

[69]  R Simon,et al.  Measures of explained variation for survival data. , 1990, Statistics in medicine.

[70]  P. Holland.  Causal Inference, Path Analysis and Recursive Structural Equations Models. Program Statistics Research, Technical Report No. 88-81. , 1988 .

[71]  Christopher Winship,et al.  Structural Equations and Path Analysis for Discrete Data , 1983, American Journal of Sociology.

[72]  G. Brier,et al.  External correspondence: Decompositions of the mean probability score , 1982 .

[73]  T. Bolin,et al.  OF HEALTH , 2022 .